Potential T regulatory cell therapy in transplantation: How far have we come and how far can we go?

Research output: Contribution to journalArticle

Abstract

Graft survival has been lately improved by the introduction of efficient immunosuppressive drugs. However, late graft loss caused by chronic rejection and the side effects of long-term immunosuppression remain major obstacles for successful transplantation. Operational tolerance, which is defined by the lack of acute and chronic rejection and indefinite graft survival with normal graft function in the absence of continuous immunosuppression, represents an attractive alternative. Nevertheless, tolerance after allogeneic transplantation is commonly considered the 'mission impossible' for both immunologists and clinicians. One of the mechanisms involved in tolerance is the suppression of graft-specific alloreactive T cells, which largely mediate graft rejection, by regulatory T cells (Tregs) or by soluble factors produced by Treg cells. With this review, I will make an effort to collect and describe the significant studies performed in transplanted patients, and not in animal models or in in vitro systems, with the attempt to: (i) understand how tolerance is achieved, (ii) define whether and how Treg cells influence transplant tolerance, (iii) describe the first clinical trials with Treg cells in humans (i.e. how far have we come) and (iv) predict the future of Treg cell-based therapy in humans (i.e. how far can we go).

Original languageEnglish
Pages (from-to)761-770
Number of pages10
JournalTransplant International
Volume23
Issue number8
DOIs
Publication statusPublished - 2010

Fingerprint

Regulatory T-Lymphocytes
Cell- and Tissue-Based Therapy
Transplantation
Transplants
Graft Survival
Immunosuppression
Homologous Transplantation
Graft Rejection
Immunosuppressive Agents
Animal Models
Clinical Trials
T-Lymphocytes
Pharmaceutical Preparations

Keywords

  • regulatory T cells
  • tolerance
  • transplantation

ASJC Scopus subject areas

  • Transplantation
  • Medicine(all)

Cite this

Potential T regulatory cell therapy in transplantation : How far have we come and how far can we go? / Battaglia, Manuela.

In: Transplant International, Vol. 23, No. 8, 2010, p. 761-770.

Research output: Contribution to journalArticle

@article{136b1f69b12f4beeb2c4b53c1b118a71,
title = "Potential T regulatory cell therapy in transplantation: How far have we come and how far can we go?",
abstract = "Graft survival has been lately improved by the introduction of efficient immunosuppressive drugs. However, late graft loss caused by chronic rejection and the side effects of long-term immunosuppression remain major obstacles for successful transplantation. Operational tolerance, which is defined by the lack of acute and chronic rejection and indefinite graft survival with normal graft function in the absence of continuous immunosuppression, represents an attractive alternative. Nevertheless, tolerance after allogeneic transplantation is commonly considered the 'mission impossible' for both immunologists and clinicians. One of the mechanisms involved in tolerance is the suppression of graft-specific alloreactive T cells, which largely mediate graft rejection, by regulatory T cells (Tregs) or by soluble factors produced by Treg cells. With this review, I will make an effort to collect and describe the significant studies performed in transplanted patients, and not in animal models or in in vitro systems, with the attempt to: (i) understand how tolerance is achieved, (ii) define whether and how Treg cells influence transplant tolerance, (iii) describe the first clinical trials with Treg cells in humans (i.e. how far have we come) and (iv) predict the future of Treg cell-based therapy in humans (i.e. how far can we go).",
keywords = "regulatory T cells, tolerance, transplantation",
author = "Manuela Battaglia",
year = "2010",
doi = "10.1111/j.1432-2277.2010.01127.x",
language = "English",
volume = "23",
pages = "761--770",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "8",

}

TY - JOUR

T1 - Potential T regulatory cell therapy in transplantation

T2 - How far have we come and how far can we go?

AU - Battaglia, Manuela

PY - 2010

Y1 - 2010

N2 - Graft survival has been lately improved by the introduction of efficient immunosuppressive drugs. However, late graft loss caused by chronic rejection and the side effects of long-term immunosuppression remain major obstacles for successful transplantation. Operational tolerance, which is defined by the lack of acute and chronic rejection and indefinite graft survival with normal graft function in the absence of continuous immunosuppression, represents an attractive alternative. Nevertheless, tolerance after allogeneic transplantation is commonly considered the 'mission impossible' for both immunologists and clinicians. One of the mechanisms involved in tolerance is the suppression of graft-specific alloreactive T cells, which largely mediate graft rejection, by regulatory T cells (Tregs) or by soluble factors produced by Treg cells. With this review, I will make an effort to collect and describe the significant studies performed in transplanted patients, and not in animal models or in in vitro systems, with the attempt to: (i) understand how tolerance is achieved, (ii) define whether and how Treg cells influence transplant tolerance, (iii) describe the first clinical trials with Treg cells in humans (i.e. how far have we come) and (iv) predict the future of Treg cell-based therapy in humans (i.e. how far can we go).

AB - Graft survival has been lately improved by the introduction of efficient immunosuppressive drugs. However, late graft loss caused by chronic rejection and the side effects of long-term immunosuppression remain major obstacles for successful transplantation. Operational tolerance, which is defined by the lack of acute and chronic rejection and indefinite graft survival with normal graft function in the absence of continuous immunosuppression, represents an attractive alternative. Nevertheless, tolerance after allogeneic transplantation is commonly considered the 'mission impossible' for both immunologists and clinicians. One of the mechanisms involved in tolerance is the suppression of graft-specific alloreactive T cells, which largely mediate graft rejection, by regulatory T cells (Tregs) or by soluble factors produced by Treg cells. With this review, I will make an effort to collect and describe the significant studies performed in transplanted patients, and not in animal models or in in vitro systems, with the attempt to: (i) understand how tolerance is achieved, (ii) define whether and how Treg cells influence transplant tolerance, (iii) describe the first clinical trials with Treg cells in humans (i.e. how far have we come) and (iv) predict the future of Treg cell-based therapy in humans (i.e. how far can we go).

KW - regulatory T cells

KW - tolerance

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=77954485583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954485583&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2010.01127.x

DO - 10.1111/j.1432-2277.2010.01127.x

M3 - Article

C2 - 20553440

AN - SCOPUS:77954485583

VL - 23

SP - 761

EP - 770

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 8

ER -